Resources

Clinical data

150,000+

total patients treated

98.2%

sentinel lymph node detection rate

93.4%

nodal malignancy detection per patient

95.5%

nodal detection rate

2.3

average nodes obtained per patient

Meta-analysis which shows how the Magtrace® lymphatic tracer is superior to blue dye alone and comparable to dual tracer.

Mok et al (2019)

This US based multi-centre prospective study finds the Magtrace® lymphatic tracer is non-inferior to the standard technique for SLNB

Alvarado et al (2019)

A safety study showing the Magtrace® lymphatic tracer to be safe with a low risk of complications

Lorek et al (2019)

The largest cohort of the Magtrace® lymphatic tracer-only application for SLNB, providing simpler logistics and operative planning with excellent clinical results

Man et al (2019)

A study showing the combined use of the Magseed® marker and Magtrace® lymphatic tracer for lesion localisation and SLNB

Pohlodek et al (2019)

This study shows that the Magtrace® lymphatic tracer spared DCIS patients the need for unnecessary SLNB by enabling a delayed SLNB technique

Karakatsanis et al (2019)

A study demonstrating accurate lesion localisation and SLN detection with the combined use of the Magseed® marker and Magtrace® lymphatic tracer

Hersi et al (2018)

A study showing that Magtrace® lymphatic tracer is non-inferior to Tc99 and offers both cost and availability benefits to radioisotope

Ghilli et al (2017)

The MONOS study evaluates the use of the Magtrace® lymphatic tracer as the sole tracer used in SLNB

Karakatsanis et al (2017)

Meta-analysis demonstrating how Magtrace® lymphatic tracer is non-inferior to standard Tc99, with or without Blue dye

Teshome et al (2016)

Meta-analysis showing Magtrace® lymphatic tracer is non-inferior to Tc99 and blue dye

Zada et al (2016)

This study shows that the Magtrace® lymphatic tracer is a safe and effective alternative to the standard technique

Karakatsanis eta al (2016)

This study shows that the Magtrace® lymphatic tracer is a valuable alternative to radioisotope and blue dye

Piñero-Madrona et al (2015)

A study showing that Magtrace® lymphatic tracer is non-inferior to radiotracer and is oncologically safe

Rubio et al (2015)

A feasibility study showing the Magtrace® lymphatic tracer as a contrast agent in MRI to provide pre-op imaging localisation of sentinel lymph nodes

Pouw et al (2015)

A study showing the feasibility of the Magtrace® lymphatic tracer for lesion localisation combined with periareolar injection of blue dye for SLNB

Ahmed et al (2015)

A study showing Magnetic SLNB can be performed easily, safely and equivalently well in comparison to radioisotope alone

Thill et all (2014)

This study shows that the Magtrace® lymphatic tracer is a feasible technique for SLNB with detection rates non-inferior to standard technique

Douek et al (2013)